Fig. 6: In vivo anti-tumor efficacy on a CSC-enriched subcutaneous model. | Nature Communications

Fig. 6: In vivo anti-tumor efficacy on a CSC-enriched subcutaneous model.

From: Self-assembled aldehyde dehydrogenase-activatable nano-prodrug for cancer stem cell-enriched tumor detection and treatment

Fig. 6

a Process of the in vivo efficacy study in 4T1-subcutaneous mice model, and all mice were intravenously administrated by G1-G7 groups. Created in BioRender. Jiajing, G. (2023) BioRender.com/v30s379. b–h Tumor growth of subcutaneous 4T1 tumor-bearing mice after G1-G7 treatments. i Tumor volume growth of each mouse from G1-G7 groups at the end of 21 days treatment (n = 5 independent biological samples; means ± SD). j Photograph of excised tumors from G1-G7 groups at the end of 21 days treatment. k Average tumor weight excised from G1-G7 groups at the end of 21 days treatment (n = 5 independent biological samples; means ± SD). l H&E staining of the tumor tissues from G1-G7 groups after different treatments. Scale bar: 200 μm. m The changes in body weights of subcutaneous 4T1 tumor-bearing mice in G1-G7 groups within 21 days (n = 5 independent biological samples; means ± SD). L: white light (60 mW/cm2, 5 min). The statistical significance is analyzed by one-way ANOVA with a Tukey post hoc test, ****p < 0.0001. Saline (G1), PS-CHO + L (G2), ATRA-SS-ATRA (G3), PS-CHO@ATRA-SS-ATRA (G4), PS-CHO@HA-DSPE-PEG2000 + L (G5), PS-CHO@ATRA-SS-ATRA + L (G6), and PS-CHO@HA-ATRA-SS-ATRA + L (G7).

Back to article page